Wednesday, 13 May 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 13 May 2026
News

BMS bets big on US$15B deal

Posted 13 May 2026 PM

BMS has signed a US$15 billion megadeal with China's largest pharmaceutical company Hengrui to advance 13 early stage therapies in oncology, haematology and immunology.

The agreement covers four oncology/haematology assets from Hengrui, four immunology assets from BMS, and five innovative assets to be jointly discovered and developed by both companies.

To see the whole article, please login

Popular

Aussie expat scores top global job
Who's opening in Waterloo?
PBAC July Agenda blows out to 58
AZ drug facing headwinds
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home